AIRLINK 58.74 Increased By ▲ 0.75 (1.29%)
BOP 6.20 Decreased By ▼ -0.02 (-0.32%)
CNERGY 3.95 Decreased By ▼ -0.10 (-2.47%)
DFML 16.08 Increased By ▲ 0.38 (2.42%)
DGKC 67.48 Decreased By ▼ -1.07 (-1.56%)
FCCL 17.59 Decreased By ▼ -0.16 (-0.9%)
FFBL 25.91 Increased By ▲ 0.16 (0.62%)
FFL 9.17 Decreased By ▼ -0.14 (-1.5%)
GGL 9.82 Increased By ▲ 0.08 (0.82%)
HBL 112.95 Increased By ▲ 1.15 (1.03%)
HUBC 114.99 Increased By ▲ 0.19 (0.17%)
HUMNL 6.58 Increased By ▲ 0.14 (2.17%)
KEL 4.20 Decreased By ▼ -0.10 (-2.33%)
KOSM 3.59 Increased By ▲ 0.01 (0.28%)
MLCF 37.35 Decreased By ▼ -0.05 (-0.13%)
OGDC 116.69 Decreased By ▼ -0.51 (-0.44%)
PAEL 22.74 Decreased By ▼ -0.16 (-0.7%)
PIAA 10.76 Decreased By ▼ -0.59 (-5.2%)
PIBTL 6.22 Increased By ▲ 0.55 (9.7%)
PPL 104.26 Decreased By ▼ -0.99 (-0.94%)
PRL 26.47 Decreased By ▼ -0.08 (-0.3%)
PTC 9.55 Decreased By ▼ -0.05 (-0.52%)
SEARL 52.00 Decreased By ▼ -1.34 (-2.51%)
SNGP 65.15 Increased By ▲ 0.16 (0.25%)
SSGC 10.93 Decreased By ▼ -0.01 (-0.09%)
TELE 7.26 Increased By ▲ 0.10 (1.4%)
TPLP 11.97 Increased By ▲ 0.10 (0.84%)
TRG 77.22 Increased By ▲ 4.51 (6.2%)
UNITY 20.44 Decreased By ▼ -0.29 (-1.4%)
WTL 1.29 Decreased By ▼ -0.02 (-1.53%)
BR100 6,332 Increased By 45.7 (0.73%)
BR30 21,614 Increased By 27.8 (0.13%)
KSE100 61,914 Increased By 355.2 (0.58%)
KSE30 20,851 Increased By 132.3 (0.64%)

Panadol is short in the market and this has been catching eyes of media, politicians, all and sundry. Everyone has an opinion on it. Some believe the producer, in this case, the company (GSK Consumer Healthcare) is insensitive to reduce production of Panadol at a time when it is needed most with demand rising due to dengue outspread and other exogenous factors like floods. Some are blaming the government, as drug prices are regulated in Pakistan where the price revision of Panadol (and 40 other products) recommended by the Drug Regulatory Authority of Pakistan was rejected by the Federal Cabinet. Eventually that led to the declaring of force majeure on the production of three Panadol variants -Panadol Tablets, Panadol Extra Tablets, and children’s Panadol Liquid Range, by GSKHC who believe that they are unable to cover their costs based on current prices.

The company is making a commercial decision. One can argue with the timings and insensitivity of it to a product needed for children; but the issue is deeper and wider- much beyond one company or one generic product (paracetamol).

All the drug prices in Pakistan are regulated by the Federal Government and there is too much regulation. In the developed world – UK and US, particularly, there is no price fixing. Meanwhile, in countries like India and Bangladesh, only WHO essential list (130 odd products including Panadol Tablet – not other products) have price regulations. For long-term sustainable model, Pakistan needs to slowly deregulate the pricing.

Panadol (or generic paracetamol) is not the only company (or product) that is facing cost pressures. There are many other products. In August 2022, 35 products (including 3 Panadol variants) price increase proposal from health ministry as ‘hardship category’ was rejected by the federal government. Later, In September 2022, another 10 products under hardship category were also rejected by the PDM government.

Hardship category consists of products where there is an unusual growth in cost and where production becomes unviable. Their cost is being analyzed by the government before moving the summary. In these products, the production becomes unviable without price increase.

There are political pressures on the government to not increase the prices as Shahbaz and others fear strong backlash from PTI and masses on the price increase. And it appears all the government cares about is its political capital, all else is someone else’s headache. Having said that, the issue is being brewing over the last one year (if not more). The summary of price increase was sent to the then PTI government in January 2021. And then, PM IK was reluctant to increase the price. And then came VONC. And now the new government is getting cold feet. The issue is like petroleum prices where the efforts to save political capital by successive governments is doing the damage.

Panadol is a big brand and has wide visibility. A couple of months back, the company decided to reduce the production of a few Panadol variants to one third. That had created a shortage in the market. But the company’s decision was based on the rejection of government for price revision of hardship products. Now the company is going a step further.

According to GSKCH, In Paracetamol adult category Panadol variants share is 80 percent. And the company claims that many other producers of paracetamol have already shut operations. But these are hardly noticed. There are over 100 other brands that have market share of 20 percent. The API of paracetamol is being produced (rather assembled) locally and imported as well. As per channel checks from the local API producer (Citi Pharma), out of its average 460 tons monthly production, GSKCH usually buys 300 tons. Apart from that, GSKCH also imports API. The supply from Cit Pharma to GSK has reduced to 100 tons a month and supply to others had remained unchanged till the last month. There is some dip in the ongoing month.

This implies that other producers are still producing paracetamol – albeit there are signs of decline. The market intelligence suggest that local small companies are selling at higher than permitted price and the product is selling in black at higher prices. GSKCH being an MNC has to comply with the global ethics standards. Market intelligence also suggests that Panadol variants are selling at Rs70-100 per strip in different cities – 3-4 times the market retail price (MRP), in black. The bottom line is that overall paracetamol is being short, and the consumer is paying a higher price. That defeats the government’s purpose to have people buy the drug at an affordable price.

The company is in talks with the government. And the government is mainly focusing on the brand Panadol due to its media hype. The problem is much wider. The grapevine is that the government is thinking of giving subsidy to the brand; but not ready to increase prices. That is not a wise decision. The government is not thinking through the problem. This will open a pandora box.

First, there are 45 items in the hardship category. How can government merely provide subsidy to three variants of Panadol. As per GSKCH, the monthly gross loss on today’s cost, is Rs200 million for its adult Panadol two variants. This number will mushroom. And without solving the problem, many other products are going to be short in the market – already some are, but they haven’t gotten any media attention yet.

Moreover, the Pakistan Pharmaceutical Manufacturing Association (PPMA)has written letters to DRAP, health ministry and the PM on 38 percent increase in drug prices across the board on all drug products in the country. The government didn’t reply. The drug policy board is dysfunctional for the six months or so. That is a sad situation. And now the PPMA is routing through Islamabad High Court to get a reply from DRAP. If the issue is unsolved, sooner or later, many products would be short in the market; supplied at premiums in the black market. The Panadol case is just a trailer to a much bigger crisis in the making.

Comments

Comments are closed.

Hassaan Oct 25, 2022 10:59am
Quality Drug Producers will slowly divest, which is already happening since early 90’s… Regulator to regulate Quality only (which they don’t) and than essential drugs like underdevelopment countries, and let the market forces decide on sales and marketing strategies. Giver control prices of fuel, which they change every fortnight, while basic medicines prices are also triggered by global trends as well as exchange rates and demand supply equation.
thumb_up Recommended (0)
Hashmi Oct 25, 2022 11:12am
Has the Government of Pakistan ever been blamed for its slow or no responses or delayed or no decisions ever ? The GOP is in an ostrich mode keeping its head in the ground whilst the economic tornado is hitting and bitting off its skin and feathers. Don’t we know where the costs of inputs and production has gone ? For both our local and foreign companies base materials are imported. None of these companies are social institutions. And none will work if there is no profit. Call it insensitivity or whatever.
thumb_up Recommended (0)
muftikhalid Oct 26, 2022 12:39pm
It seems highly strange and deplorable that federal cabinet has rejected the proposal of DRAP in increasing the price of Panadol leading towards the end of manufacturing by GSK. It is undoubtedly a political decision due to fear of protest from PTI. This drug has been the main component of providing some relief to our poverty ridden population particularly after the devastating floods. The decision must be reviewed immediately because whether the drug prices are lowered or risen it does not affect the mood of PTI which is ready to hold long March and sittings in islamabad. The PML N government has failed miserably in all fronts and it could add to their agony if the drug shortages become rampant.
thumb_up Recommended (0)
Anonymous Oct 26, 2022 04:47pm
These Pharma companies are becoming Mafias. The point to raise prices of a medicine when it is needed most creates significant doubt about their role to black mail government and public at the same time. Why don't they were held accountable for giving commissions and incentives to the Doctors for prescribing a particular medicine/drug? What penal actions including suspension of license were taken against these companies?
thumb_up Recommended (0)
Javed Chaudhry Oct 26, 2022 06:03pm
We do not want unregulated model like US for medical and pharma sectors. In US, there is practically no right to medical care for the poor. Every welfare state from UK, Canada, EU, Turkey to Australia and New Zealand have drug price controls. Pakistan must NOT bow to the pressure tactics from capitalist mafias in medical and pharma world. Similar tactics are being used by equivalent headache drug manufacturers of Tylenol (Generic Name Acetamonophen) in Canada.
thumb_up Recommended (0)